Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.43 |
| ▸ | CDC25B | P30305 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111162 | 0.92 | CDC25A (0.45) | CDC25ACDC25BHTTAPEX1ITGAV | |
| SCHEMBL5115200 | 0.91 | FABP4 (0.46) | CDC25ACDC25BHTTAPEX1ITGAV | |
| SCHEMBL5393177 | 0.84 | ITGAV (0.44) | ITGAVMCOLN3ALDH1A1PGRERCC5 | |
| SCHEMBL5125393 | 0.83 | KMT2A (0.39) | HTTITGAVMCOLN3ALDH1A1PGR | |
| SCHEMBL5384990 | 0.82 | DRD2 (0.37) | ITGAVMCOLN3 | |
| SCHEMBL6884908 | 0.80 | POLB (0.44) | CDC25AITGAVCA1CA2MCOLN3 | |
| SCHEMBL12916500 | 0.79 | FABP4 (0.51) | CDC25ACDC25BAPEX1ITGAVFABP4 | |
| SCHEMBL5117224 | 0.79 | FABP4 (0.51) | CDC25ACDC25BHTTCA1CA2 | |
| SCHEMBL5118899 | 0.77 | ITGAV (0.40) | ITGAVMCOLN3PGRERCC5FEN1 | |
| SCHEMBL5118903 | 0.77 | ITGAV (0.40) | ITGAVMCOLN3PGRERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | CDC25A 2035/4885CDC25B 2509/4885HTT 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.